TB-500 vs Thymosin Beta-4
TB-500 and thymosin beta-4 are not safe synonyms. Full-length human thymosin beta-4 is a 43-residue peptide. The 2012 analytical paper that examined a preparation marketed as TB-500 identified an N-terminally acetylated seven-residue fragment, Ac-LKKTETQ. A laboratory should therefore resolve the exact supplied identity before interpreting either analytical data or biological literature.
Quick identity comparison
| Feature | Thymosin beta-4 | TB-500 in the Esposito analytical paper |
|---|---|---|
| Peptide scope | Full-length 43-residue parent peptide | Seven-residue fragment from thymosin-β4 positions 17–23, with N-terminal acetylation (Ac-LKKTETQ) |
| Fragment identity | Contains the LKKTETQ region within the full sequence | Ac-LKKTETQ |
| Analytical implication | Expected mass/fragmentation belongs to the full peptide | Expected mass/fragmentation belongs to the acetylated fragment |
| Can the names be interchanged? | No. The exact material used in the paper or supplied lot must be stated. | |
How to read “17–23”: These numbers are residue positions within the 43-residue parent peptide, not a length range. Ac-LKKTETQ contains seven amino acids with an N-terminal acetyl group. Esposito et al. characterised the material in a specific TB-500-labelled sample; that finding does not establish the chemical form in any other supplier’s lot. For the Core Research TB-500 10mg presentation, use its own applicable batch documentation. Esposito et al. (2012), PMID 22962027.
What the TB-500 analytical paper established
Esposito and colleagues used chromatographic separation and high-resolution mass spectrometry to identify Ac-LKKTETQ in a product marketed as TB-500. PubMed. An equine doping-control study subsequently developed LC-MS methods around the same short acetylated fragment and its metabolites. PubMed.
These papers provide an analytical anchor for the material they tested. They do not prove that every product sold under the TB-500 name has the same identity.
Why full-length thymosin beta-4 is a different research entity
Mutational analysis of full-length thymosin beta-4 shows that actin binding involves more than the central short motif; contributions from the N-terminal region and central sequence are both important. PubMed.
This is why “active domain” language should be handled carefully. A short fragment can preserve a biologically interesting sequence without reproducing every structural or functional property of the 43-residue parent.
LKKTETQ and Ac-LKKTETQ should also be separated
Some biological studies use unacetylated LKKTETQ, while the analytical TB-500 paper identifies Ac-LKKTETQ. Terminal acetylation changes the chemical entity. A finding for one form should not be silently reported as a finding for the other.
What to verify in a TB-500 product record
- Supplier-declared sequence and terminal groups.
- Expected mass/ion assignment for that declared form.
- HPLC method and chromatographic result.
- Product name, lot identifier and report all referring to the same material.
- Any counter-ion or water information that affects mass/content calculations.
If a product, label or report uses “TB-500” without enough structural information to distinguish the material, record the identity as unresolved rather than completing it from a different source.
Biological findings remain form- and model-specific
Short-fragment studies include aged-mouse dermal work, stimulated hepatic-stellate-cell experiments and parent/metabolite comparisons. These findings are explained in the TB-500 research overview. They should not be transferred to full-length thymosin beta-4 or to a commercial product without matching identity.
Research-use boundary
This guide provides nomenclature and analytical disambiguation. It does not provide wound-healing, treatment, dosing or administration guidance. Core Research products are supplied for laboratory research only.
Selected references
- Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500. 2012. PMID 22962027.
- Ho ENM, et al. Doping control analysis of TB-500 in equine urine and plasma by LC-MS. 2012. PMID 23084823.
- Van Troys M, et al. The actin binding site of thymosin beta 4 mapped by mutational analysis. 1996. PMID 8617195.